Solara Active Pharma Sciences Limited
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Solara Active Pharma Sciences Limited - overview
Established
2018
Location
Chennai, Tamilnadu, India
Primary Industry
Pharmaceuticals
About
Based in India, Solara Active Pharma Sciences Limited focuses on the production of Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, ensuring high-quality solutions for diverse medical needs. Solara Active Pharma Sciences Limited specializes in the development and manufacturing of APIs. Founded in 2018, the company is headquartered in Chennai, India. In January 2020, TPG invested INR 600 million in a PIPE funding round, bringing the total amount raised to INR 600 million.
The company has successfully completed two significant deals, demonstrating its growth trajectory under the leadership of CEO Poorvank P. Solara Active Pharma Sciences specializes in the production of Active Pharmaceutical Ingredients (APIs), primarily for the pharmaceutical industry. The company develops and manufactures high-quality APIs that serve as essential components in various therapeutic formulations. Their products address numerous medical needs globally, enhancing patient quality of life.
Solara caters to a diverse clientele, including pharmaceutical companies and contract research organizations (CROs) that use their products in drug development across multiple therapeutic areas. The company maintains a presence in North America, Europe, and Asia, ensuring its innovative solutions are accessible to healthcare providers and patients worldwide. In the most recent fiscal year, 2021, Solara Active Pharma Sciences reported a revenue of INR 217,829,174. 50 and an EBITDA of INR 53,945,350.
30. Their revenue generation strategy relies on B2B transactions with pharmaceutical companies and CROs, where clients procure APIs for drug formulations through partnerships and contractual agreements, often sold in bulk to healthcare manufacturers. Looking ahead, Solara Active Pharma Sciences plans to leverage the recent investment of INR 600 million from TPG to support the design and launch of new products in the API sector. The company is targeting expansion into additional markets in Europe and North America by the end of 2023.
This growth strategy is expected to enhance their market reach and strengthen their position within the pharmaceutical supply chain.
Current Investors
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
www.solara.co.in/
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Solara Active Pharma Sciences Limited - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Solara Active Pharma Sciences Limited | - | ||||||||
| PIPE | Completed | Solara Active Pharma Sciences Limited | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.